Features | Partner Sites | Information | LinkXpress
Sign In
CARDIOSTIM
Schiller
Primedic

Medtronic Buys Tyrx Antibacterial Envelope Manufacturer

By HospiMedica International staff writers
Posted on 13 Jan 2014
Startup company Tyrx (Monmouth Junction, NJ, USA), which manufactures bioresorbable envelopes for implanted medical devices, is now a part of Medtronic (Minneapolis, MN, USA), the world's largest medical device company.

The acquisition supports Medtronic's expansion of its medical device product offerings to include broader healthcare services and solutions, providing meaningful clinical outcomes and economic value for hospitals, physicians, patients, and payers. TYRX brings to Medtronic the AIGISRx R fully resorbable antibacterial envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs), and the AIGISRx N antibacterial envelope, used with spinal cord neurostimulators.

The bioresorbable envelopes use a combination of two antibiotic drugs: Minocycline and Rifampin. Minocycline is a tetracycline-class antibiotic commonly used to treat skin acne, among other things; Rifampin is commonly used to treat tuberculosis. Both drugs have different modes of action, and working together target roughly 80% of the germs, which can be introduced during surgery, including Methicillin Resistant Staphylococcus aureus (MRSA) and a number of other pathogens.

“While the risk of infection from an implanted pacemaker or defibrillator is low for most patients, repeated operative procedures after the initial device implant are associated with a substantial incremental risk of infection. This is estimated to cost the US healthcare system more than one billion dollars per year,” said Pat Mackin, president of the cardiac rhythm disease management business and senior vice president at Medtronic. “TYRX has developed an innovative, proven technology to reduce infection risk, making the procedure safer for patients and removing significant costs from the healthcare system.”

“We look forward to joining Medtronic as part of a combined portfolio that can positively impact outcomes for patients by reducing implant-related infections, and bring value to our customers,” said Robert White, president and CEO of Tyrx.

The all-cash transaction includes an initial payment of USD 160 million plus potential earn out and performance based milestone payments.

Related Links:

Tyrx
Medtronic
Antibacterial Envelope Protects Cardiac Implants




Channels

Surgical Techniques

view channel
3-D Printing Helps Rehearse Complex Brain Procedures

3-D Printing Helps Rehearse Complex Brain Procedures

A new study describes how custom, high–fidelity three-dimensional (3-D) printed models of brain vessel malformations can be used to rehearse pediatric surgical procedures. Researchers at Boston Children’s... Read more

Women's Health

view channel

Fetal ECG Readings Offer No Advantage During Labor

A new technology that provides electrocardiogram (ECG) readings of the fetus heart during the birth process offers no advantages over conventional monitoring, according to a new study. Researchers at the US National Institute of Child Health and Human Development (NICHD; Bethesda, MD, USA), the University of Texas Medical... Read more

Hospital News

view channel
Image: The future site of the Springdale ACH campus on I-49, across from Arvest Ballpark (Photo courtesy of ACH).

Arkansas Children's Hospital to Develop Springdale Facility

Arkansas Children's Hospital (ACH; Little Rock, USA) has unveiled plans to develop a new hospital campus in Springdale, which will involve an investment of USD 184 million during the next five years.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.